About Deargen
Deargen is a Healthcare company based in Seoul (South Korea) founded in 2016. Developer of AI-based drug discovery platform for rare and intractable diseases. Deargen has raised $17 million across 1 funding round from investors including Korean Development Bank, Nvester and The Wells Investment. Its chief executive, as recorded, is Gilsu Kang. Deargen offers products and services including Dr. UG, DearTRANS, WX Biomarker Prediction, DearDTI, and MolEQ. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is Deargen Co., Ltd.
Company details
Deargen was founded in 2016 in Seoul, South Korea, within the biotechnology sector. An AI-driven platform is operated to address rare and intractable diseases through genome data analysis, biomarker prediction, molecule selection, and optimization processes. New disease targets are identified via this technology to support the development of small molecule precision medicines. Operations focus on accelerating drug discovery for underserved medical needs.
- Headquarters Seoul, South Korea
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website deargen.me
- Social LinkedIn
- Legal Name Deargen Co., Ltd
- Total Equity Funding$17M (USD)
in 1 rounds
- Latest Funding Round$17M (USD), Series B
Feb 2022
- InvestorsKorean Development Bank
& 4 more
Products & Services of Deargen
Deargen offers a comprehensive portfolio of products and services, including Dr. UG, DearTRANS, WX Biomarker Prediction, DearDTI, and MolEQ.
AI tool for drug development via deep learning technology.
Service for analyzing genome data in drug research.
Platform for predicting biomarkers in precision medicine.
Tool for selecting molecules in drug optimization.
System for optimizing drug leads using AI.
Funding Insights of Deargen
Deargen has successfully raised a total of $17M through 1 strategic funding round. The most recent funding activity was a Series B round of $17 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 1
- Last Round Series B — $17M
- First Round $17M
(Feb 2022)
- Investors Count 5
All 1 funding rounds of Deargen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2022 | $17M | Series B | – | Nvester, The Wells Investment | – |
5 investors in total: 5 institutional.
Investors in Deargen
Deargen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Korean Development Bank, Nvester and The Wells Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in South Korea are managed. | investwells.com | Seoul, South Korea | ||
Financial support is provided to ventures by Hana Ventures. | hanaventures.co.kr | Seoul, South Korea | ||
Delivers comprehensive financial services tailored for the investment industry. | 2015 | nvestor.co.kr | Seoul, South Korea | |
Development financing and commercial banking are provided in South Korea. | 1954 | kdb.co.kr | Seoul, South Korea | |
Operates as an investment firm based in South Korea. | 2008 | tsinvestment.co.kr | Seoul, South Korea |
Investor details for Deargen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Deargen
6 people are tracked at Deargen (4 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Gilsu Kang | CEO | Leadership |
Suhyeon (Sean) Kim | Director of Strategic Planning | Leadership |
성수 박 | Chief Technology Officer | Leadership |
Andrew Ha | BD Director | Leadership |
Jong Young Joung | Research Scientist & Team Leader | Team |
Young-Heon Kim | 연구원 | Team |
Complete people profiles for Deargen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Deargen
2 dated milestones of Deargen across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Deargen is founded.
- Funding First funding round of $17.0M.
Web traffic of Deargen
The website of Deargen (deargen.me) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 5.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Deargen
Deargen was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Deargen is headquartered in Seoul, South Korea.
Gilsu Kang is the CEO of Deargen, as recorded in our data.
Deargen is a funded company, having raised a total of $17M across 1 funding round to date. The company's 1st funding round was a Series B of $17M, raised on Feb 2022.
Deargen was founded in 2016 in Seoul, South Korea, within the biotechnology sector. An AI-driven platform is operated to address rare and intractable diseases through genome data analysis, biomarker prediction, molecule selection, and optimization processes. New disease targets are identified via this technology to support the development of small molecule precision medicines. Operations focus on accelerating drug discovery for underserved medical needs.
Deargen offers Dr. UG, DearTRANS, WX Biomarker Prediction, DearDTI, and MolEQ.
Deargen has 5 investors. Key investors include Korean Development Bank, Nvester, The Wells Investment, T S Investment, and Hana Ventures.
Deargen operates through Deargen Co., Ltd.